Search

Your search keyword '"Noventa, F"' showing total 36 results
Start Over Author "Noventa, F" Publisher elsevier bv
36 results on '"Noventa, F"'

5. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy

Author

Fabris, P., primary, Noventa, F., additional, Pasulo, L., additional, Farina, F., additional, Carollo, G., additional, Carlotto, A., additional, Rovere, P., additional, Cavinato, S., additional, Romano, A., additional, Vario, A., additional, Fraceschet, I., additional, Panese, S., additional, Bertin, T., additional, Zappalà, F., additional, Alberti, A., additional, Lobello, S., additional, Aghemo, A., additional, Bruno, R., additional, Puoti, M., additional, Rizzardini, G., additional, Spinelli, O., additional, Pigozzi, MG., additional, Spinetti, A., additional, Menzaghi, B., additional, Pan, A., additional, Bella, D., additional, Re, T., additional, Borghi, M., additional, Lombardi, A., additional, Viganò, M., additional, Salpietro, S., additional, Lleo, A., additional, and Fagiuoli, S., additional

Published
2020
Full Text
View/download PDF

6. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

Author

Pasulo, L., primary, Gambato, M., additional, Spinetti, A., additional, D’Ambrosio, R., additional, Puoti, M., additional, Ciancio, A., additional, Di Marco, V., additional, Calvaruso, V., additional, Colombatto, P., additional, Brunetto, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Pozzan, C., additional, Vinci, M., additional, Viganò, M., additional, Lombardi, A., additional, Bello, S. Lo, additional, Zuin, M., additional, Aghemo, A., additional, Rumi, M.G., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, D’Arminio Monforte, A., additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Soffredini, R., additional, Colpani, M., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Cologni, G., additional, Cartabellotta, F., additional, Di Lorenzo, F., additional, Cacciola, I., additional, Albanese, A., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Capretti, A., additional, Memoli, M., additional, Rossi, C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A.E., additional, Dibenedetto, C., additional, Magni, C.F., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional

Published
2019
Full Text
View/download PDF

7. Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform

Author

Russo, F.P., primary, Gambato, M., additional, Romano, A., additional, Piovesana, S., additional, Cattelan, A., additional, Bello, Lo, additional, Rossi, C., additional, Vanin, V., additional, Panese, S., additional, Franceschet, I., additional, Pozzan, C., additional, Paon, V., additional, Carolo, G., additional, Vincenzi, V., additional, Chemello, L., additional, Noventa, F., additional, Angeli, P., additional, Burra, P., additional, and Alberti, A., additional

Published
2019
Full Text
View/download PDF

8. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients

Author

Gambato, M., primary, Spinetti, A., additional, Pasulo, L., additional, D’ambrosio, R., additional, Puoti, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Franceschet, I., additional, Vinci, M., additional, Viganò, M., additional, Lobello, S., additional, Zuin, M.G., additional, Aghemo, A., additional, Rumi, M., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Cattelan, F., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, Monforte, A. D’arminio, additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P.A., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Degasperi, E., additional, Soffredini, R., additional, Colpani, M., additional, Comi, L., additional, Zuccaro, V., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Capretti, A., additional, Memoli, M., additional, Pigozzi, M.G., additional, Rossi, M.C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A., additional, Dibenedetto, C., additional, Landonio, S., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional

Published
2019
Full Text
View/download PDF

9. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks

Author

Degasperi, E., primary, Spinetti, A., additional, Lombardi, A., additional, Landonio, S., additional, Scotton, P., additional, Pasulo, L., additional, Carlotto, A., additional, Giorgini, A., additional, Pozzoni, P., additional, Angeli, P., additional, Carrara, M., additional, Puoti, M., additional, Gatti, F., additional, Carolo, G., additional, Vinci, M., additional, Zoncada, A., additional, Bonfanti, P., additional, Aghemo, A., additional, Soria, A., additional, Centenaro, R., additional, Maggiolo, F., additional, Russo, F.P., additional, Rovere, P., additional, Piovesan, S., additional, Capra, F., additional, Viviani, F., additional, Morini, L., additional, Soffredini, R., additional, Carriero, C., additional, Paolucci, S., additional, Noventa, F., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional

Published
2019
Full Text
View/download PDF

10. Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study

Author

D’Ambrosio, R., primary, Pasulo, L., additional, Puoti, M., additional, Schiavini, M., additional, Viganò, P., additional, Vinci, M., additional, Menzaghi, B., additional, Zuin, M.G., additional, Soria, A., additional, Spinetti, A., additional, Aghemo, A., additional, Rumi, M.G., additional, Uberti-Foppa, C., additional, Pan, A., additional, Spinelli, O., additional, D’arminio Monforte, A., additional, Capretti, A., additional, Colli, A., additional, Colombo, A., additional, Spinzi, G., additional, Centenaro, R., additional, Buscarini, E., additional, Soffredini, R., additional, Borghi, M., additional, Colpani, M., additional, Lazzaroni, S., additional, Maggiolo, F., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Morini, L., additional, Pigozzi, M.G., additional, Dibenedetto, C., additional, Giglio, O., additional, Magni, C.F., additional, Noventa, F., additional, Lampertico, P., additional, and Fagiuoli, S., additional

Published
2018
Full Text
View/download PDF

23. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients

Author

Fattovich, G, primary, Giustina, G, additional, Degos, F, additional, Tremolada, F, additional, Diodati, G, additional, Almasio, P, additional, Nevens, F, additional, Solinas, A, additional, Mura, D, additional, Brouwer, JT, additional, Thomas, H, additional, Njapoum, C, additional, Casarin, C, additional, Bonetti, P, additional, Fuschi, P, additional, Basho, J, additional, Tocco, A, additional, Bhalla, A, additional, Galassini, R, additional, Noventa, F, additional, Schalm, SW, additional, and Realdi, G, additional

Published
1997
Full Text
View/download PDF

34. POST-TRANSFUSION HEPATITIS IN ITALY

Author

Tremolada, F., primary, Realdi, G., additional, Noventa, F., additional, Alberti, A., additional, Pornada, E., additional, Valfre, C., additional, and Gallucci, V., additional

Published
1982
Full Text
View/download PDF

35. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study

Author

Alessandra Brocchieri, Marta Borghi, Angelo Pan, Mariella Di Marco, Silvia Colombo, Chiara Molteni, Natalia Terreni, Paolo Poggio, Alberto Colombo, De Silvestri Annalisa, Riccardo Centenaro, Luisa Pasulo, Paolo Viganò, Maria Cristina Vinci, Marie Graciella Pigozzi, Stefano Fagiuoli, Pietro Lampertico, Sergio Lazzaroni, Sherrie Bhoori, Massimo Zuin, Franco Noventa, Alessio Aghemo, Barbara Menzaghi, Andrea Lombardi, Franco Maggiolo, I. Fanetti, Alessia Giorgini, Massimo Puoti, Emanuela Messina, Paolo Grossi, Roberta D'Ambrosio, Pietro Invernizzi, Monia Mendeni, Daniele Bella, E. Dionigi, Ombretta Spinelli, Maria Teresa Taddei, Pietro Pozzoni, Antonella d'Arminio Monforte, Elisabetta Buscarini, Angiola Spinetti, Serena Zaltron, D'Ambrosio, R, Pasulo, L, Giorgini, A, Spinetti, A, Messina, E, Fanetti, I, Puoti, M, Aghemo, A, Vigano, P, Vinci, M, Menzaghi, B, Lombardi, A, Pan, A, Pigozzi, M, Grossi, P, Lazzaroni, S, Spinelli, O, Invernizzi, P, Maggiolo, F, Terreni, N, Monforte, A, Poggio, P, Taddei, M, Colombo, S, Pozzoni, P, Molteni, C, Brocchieri, A, Bhoori, S, Buscarini, E, Centenaro, R, Mendeni, M, Colombo, A, Di Marco, M, Dionigi, E, Bella, D, Borghi, M, Zuin, M, Zaltron, S, Noventa, F, Annalisa, D, Lampertico, P, and Fagiuoli, S

Subjects
Male, Sustained Virologic Response, Sofosbuvir, Hepacivirus, Kidney, urologic and male genital diseases, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, MED/12 - GASTROENTEROLOGIA, eGFR, Aged, 80 and over, Hepatitis C, Middle Aged, medicine.anatomical_structure, Italy, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Glomerular Filtration Rate, Cohort study, medicine.drug, Adult, medicine.medical_specialty, SVR, Genotype, Renal function, CKD, Antiviral Agents, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Renal Insufficiency, Chronic, Aged, Retrospective Studies, Hepatology, business.industry, Ribavirin, Retrospective cohort study, Hepatitis C, Chronic, medicine.disease, Logistic Models, chemistry, business, Kidney disease
Abstract

Background: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking. Aim: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD). Methods: All HCV patients treated with DAA in Lombardy (December 2014–November 2017) with available kidney function tests during and off-treatment were included. Results: Among 3264 patients [65% males, 67% cirrhotics, eGFR 88 (9–264) ml/min], CKD stage was 3 in 9.5% and 4/5 in 0.7%. 79% and 73% patients received SOF and RBV, respectively. During DAA, eGFR declined in CKD-1 (p < 0.0001) and CKD-2 (p = 0.0002) patients, with corresponding rates of CKD stage reduction of 25% and 8%. Conversely, eGFR improved in lower CKD stages (p < 0.0001 in CKD-3a, p = 0.0007 in CKD-3b, p = 0.024 in CKD-4/5), with 33–45% rates of CKD improvement. Changes in eGFR and CKD distribution persisted at SVR. Baseline independent predictors of CKD worsening at EOT and SVR were age (p < 0.0001), higher baseline CKD stages (p < 0.0001) and AH (p = 0.010 and p < 0.0001, respectively). Conclusions: During DAA, eGFR significantly declined in patients with preserved renal function and improved in those with lower CKD stages, without reverting upon drug discontinuation.

Published
2020
Full Text
View/download PDF

36. Open Repair for Ruptured Abdominal Aortic Aneurysm: Is It Possible to Predict Survival?

Author

Sandro Lepidi, Gp Deriu, C. Maturi, Paolo Frigatti, Michele Antonello, Franco Grego, G. Pittoni, Franco Noventa, Antonello, M, Frigatti, P, Maturi, C, Lepidi, S, Noventa, F, Pittoni, G, Deriu, Gp, and Grego, F

Subjects
Male, medicine.medical_specialty, Time Factors, Multivariate analysis, Aortic Rupture, Risk Assessment, Aortic aneurysm, Aneurysm, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Health Status Indicators, Humans, Hospital Mortality, APACHE, Aged, Retrospective Studies, Aged, 80 and over, Univariate analysis, business.industry, Vascular disease, Patient Selection, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Surgery, Logistic Models, Treatment Outcome, Predictive value of tests, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Vascular Surgical Procedures, Aortic Aneurysm, Abdominal, Abdominal surgery
Abstract

The aim of the study was to determine variables that could be used to predict survival in patients with ruptured abdominal aortic aneurysm (RAAA) and to assess the accuracy of the Glasgow Aneurysm Score (GAS) and the Acute Physiology Chronic Health Evaluation II (APACHE-II). From January 1998 to July 2006, 103 patients underwent operations for RAAA. For each patient, 44 variables were retrospectively recorded in a database. Data were analyzed with univariate and multivariate methods. In the univariate analysis significant predictors of death were hypotension (p=0.001), preexisting peripheral vascular disease (p0.001), renal insufficiency (p=0.037), chronic obstructive pulmonary disease (p=0.028), level of HCO(3)(-) (p0.001), intraperitoneal rupture (p=0.001), blood transfused (p0.001), cardiac complications (p0.001), and APACHE-II score (p=0.001). Multivariate analysis confirmed statistical significance for coexisting peripheral vascular disease (p0.001), diastolic blood pressure at admission60 mm Hg (p=0.039), APACHE-II score18.5 (p=0.025), HCO(3)(-)21 mg/dL (p0.001), and intraperitoneal rupture of the aneurysm (p=0.011) as predictors of death. Results of the study suggested that different factors can be helpful in identifying those patients whose operative risk is prohibitive. APACHE-II, contrary to GAS, is an accurate system to predict postoperative death after repair for RAAA.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results